← Back to headlines
Bristol Myers Multiple Myeloma Drug Shows 50% Survival Improvement in Late-Stage Study
Bristol Myers Squibb announced that its multiple myeloma drug significantly improved patient survival by 50% in a late-stage clinical trial.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
